Spyglass Pharma (NASDAQ:SGP) Now Covered by Leerink Partners

Leerink Partners initiated coverage on shares of Spyglass Pharma (NASDAQ:SGP) in a research note issued to investors on Tuesday, MarketBeat reports. The firm issued an outperform rating and a $42.00 price objective on the stock.

A number of other analysts also recently weighed in on the company. Wall Street Zen upgraded Spyglass Pharma to a “hold” rating in a report on Tuesday, February 17th. Stifel Nicolaus assumed coverage on Spyglass Pharma in a research note on Tuesday. They issued a “buy” rating and a $42.00 price target for the company. Finally, Jefferies Financial Group assumed coverage on Spyglass Pharma in a research note on Tuesday. They issued a “buy” rating and a $62.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $47.00.

Spyglass Pharma Trading Up 0.1%

Shares of NASDAQ SGP opened at $26.75 on Tuesday. Spyglass Pharma has a 52-week low of $20.16 and a 52-week high of $32.44.

Insiders Place Their Bets

In other Spyglass Pharma news, Director Ra Capital Management, L.P. acquired 3,690,000 shares of the stock in a transaction dated Monday, February 9th. The stock was purchased at an average cost of $16.00 per share, with a total value of $59,040,000.00. Following the transaction, the director owned 5,966,439 shares in the company, valued at approximately $95,463,024. The trade was a 162.10% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Spyglass Pharma Company Profile

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).